We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

By LabMedica International staff writers
Posted on 28 Mar 2024
Print article
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane inside the ovary. Often discovered by chance in women without symptoms, ovarian cysts can also be detected during evaluations for pelvic pain. Surgical removal is a common treatment, with 5%-10% of women with ovarian cysts undergoing surgery. Of these, 13%-21% are found to have cancer upon intra-operative evaluation. The Frozen Section procedure for intra-operative evaluation that involves the slicing and microscopic examination of freeze-dried ovarian tissue aids in this determination but suffers from limitations such as unavailability, a lengthy process of up to 60 minutes, and low accuracy. The need for a swift method to differentiate between benign and malignant cysts during surgery is critical to inform management and treatment choices effectively.

INEX Innovate (Singapore) has now introduced the OvaCis Rapid Test, a novel intraoperative in vitro diagnostic (IVD) device. This test, with the ability to rapidly distinguish benign from malignant ovarian cysts within just 15 minutes, provides surgeons with immediate diagnostic data. This enables them to make quicker, more informed decisions and reduce unnecessary surgical procedures. The OvaCis Rapid Test has received regulatory approval from the Health Sciences Authority (HSA) in Singapore and is also CE-marked, and MHRA, UK registered.

Related Links:
INEX Innovate

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.